Metastatic Prostate Cancer Clinical Trial
Official title:
High-dose Testosterone in Men With Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 Deficiency
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
This is an unblinded, three cohort phase II study evaluating the efficacy of high dose testosterone (BAT) for patients with mCRPC and inactivating mutations in ATM, CDK12 or CHEK2. Patients will receive BAT until disease progression or intolerance, whichever occurs first. Throughout the study, safety and tolerability will be assessed by frequent recording of adverse events, vital signs and safety laboratory assessments. Progression will be evaluated with bone scan, CT of the abdomen/pelvis and PSA as per PCWG3 criteria. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
| Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
| Recruiting |
NCT04533958 -
Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy
|
N/A | |
| Not yet recruiting |
NCT06009549 -
A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients
|
||
| Withdrawn |
NCT05771896 -
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC
|
Phase 3 | |
| Completed |
NCT01981122 -
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT01233557 -
Biomarkers of Bone Resorption in Metastatic Prostate Cancer
|
N/A | |
| Completed |
NCT01012141 -
Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT04067713 -
Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer
|
||
| Active, not recruiting |
NCT04332744 -
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)
|
Phase 2 | |
| Completed |
NCT04545697 -
mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer
|
N/A | |
| Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04031378 -
Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer
|
Phase 2 | |
| Completed |
NCT02278055 -
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT04193657 -
Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC
|
||
| Completed |
NCT02260817 -
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
|
Phase 3 | |
| Terminated |
NCT00216060 -
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
|
Phase 3 | |
| Recruiting |
NCT04070209 -
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
|
Phase 2 | |
| Recruiting |
NCT04925648 -
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
|
Phase 2 | |
| Completed |
NCT01303705 -
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
|
Phase 1 |